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Health care costsBackground: Introduction of infant oral rotavirus vaccination in the UK in July 2013 has resulted in
decreased hospitalisations and Emergency Department (ED) visits for acute gastroenteritis (AGE), for
both adults and children. We investigated reductions in AGE incidence seen in primary care in the two
years after vaccine introduction, and estimated the healthcare costs averted across healthcare settings
in the first year of the vaccination programme.
Methods: We used primary care data from the Clinical Practice Research Datalink and age-stratified
time-series analyses to derive adjusted incidence rate ratios (IRRa) for AGE in the first two years of the
post-vaccination era (July 2013-April 2015) compared to the pre-vaccination era (July 2008-June
2013). We estimated cases averted among children aged <5 years in the first year of the vaccination pro-
gramme by comparing observed numbers of AGE cases in 2013–2014 to numbers predicted from the
time-series models. We then estimated the healthcare costs averted for general practice consultations,
ED visits and hospitalisations.
Results: In general practice, AGE rates in infants (the target group for vaccination) decreased by 15% over-
all after vaccine introduction (IRRa = 0.85; 95%CI = 0.76–0.95), and by 41% in the months of historically
high rotavirus circulation (IRRa = 0.59; 95%CI = 0.53–0.66). Rates also decreased in other young children
and to a lesser degree in older individuals, indicating herd immunity. Across all three settings (general
practice, EDs, and hospitalisations) an estimated 87,376 (95% prediction interval: 62,588–113,561) AGE
visits by children aged <5 years were averted in 2013–14, associated with an estimated £12.5 million
(9,209–16,198) reduction in healthcare costs.
Conclusions: The marked decreases in the general practice AGE burden after rotavirus vaccine introduc-
tion mirror decreases seen in other UK healthcare settings. Overall, these decreases are associated with
substantial averted healthcare costs.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rotavirus is the commonest cause of diarrhoea in young
children, and results in considerable morbidity and healthcare util-
isation [1–3]. Introduction of the monovalent live-attenuated oral
vaccine Rotarix (GlaxoSmithKline Biologicals, Rixensart, Belgium)
into national infant immunisation programmes has led to large
decreases in both rotavirus-associated and all-cause acute gas-
troenteritis (AGE) hospital admissions [4–8]. In the UK, Rotarixwas introduced in July 2013 as a 2-dose schedule given at 2 and
3 months of age. By the end of the first year, vaccine coverage
reached 93% for one dose and 88% for two doses [9]. We have
shown that vaccine introduction was followed by marked
reductions in laboratory-confirmed rotavirus infections and AGE
hospitalisations in England in the subsequent year [10]. Initial
analyses using syndromic surveillance data also showed
reductions in general practice consultations for gastroenteritis,
diarrhoea and vomiting, and in emergency department (ED) visits
for AGE [11].
Here we report in-depth analyses of the trends in incident AGE
episodes presenting to general practice in England in the first two
years after vaccine introduction (July 2013-April 2015). We also
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tings (general practice, EDs and hospital) in the first year of the
vaccination programme because of reductions in AGE cases in
young children.
2. Methods
2.1. Data sources
For the general practice analyses, we used data from the Clinical
Practice Research Datalink (CPRD). This database contains anon-
ymised primary care medical records from a representative 7%
sample of the UK population [12]. Data available include all diag-
noses and symptoms (coded using Read codes), referrals, prescrip-
tions, and feedback from secondary care.
For healthcare cost estimates, we also used data on hospitalisa-
tions and ED visits. Hospitalisation data comprised Hospital Epi-
sode Statistics (HES), which contain information on all hospital
admissions in England. ED attendance data were accessed from
the Emergency Department Syndromic Surveillance System
(EDSSS), a near real-time sentinel system that provides daily auto-
mated data extracts for ED visits [13]. We used EDSSS data from
the eighteen participating EDs in England that used International
Classification of Diseases version 10 or Snomed-CT diagnosis cod-
ing systems, to enable identification of AGE attendances.
Meteorological data, used to adjust for potential confounding by
temperature and humidity in the general practice analyses, were
downloaded from the UK Meteorological Office website and the
MIDAS Land Surface Observation database [14–16].
2.2. AGE incidence in general practice
The study period comprised July 2008-June 2013 (the pre-
vaccination period) and July 2013-April 2015 (the post-
vaccination period). Individuals’ start of follow up was the latest
of their registration date with the practice (if63 months old at reg-
istration), six months after their registration date (if >3 months old,
to avoid including historical AGE episodes recorded retrospectively
after registration), the date the practice reached established quality
standards and 1st July 2008 [17]. Follow up ended when the
patient died or left the practice, when the practice stopped provid-
ing data or 30th April 2015.
Most infectious gastroenteritis presentations to general practice
are diagnosed clinically without laboratory confirmation of the
causative pathogen. Furthermore, general practitioners (GPs) oftenFig. 1. Rates of new episodes of acute gastroenteritis (AGE) seen in Urecord gastroenteritis diagnoses using symptom codes such as ‘‘di-
arrhoea and vomiting”. We therefore used a comprehensive list of
Read codes to define AGE, categorising each code into one of four
AGE subgroups: (AGE1) infectious gastroenteritis; (AGE2) non-
infectious gastroenteritis of specified cause (e.g. ”allergic gastroen-
teritis”); (AGE3) non-infectious gastroenteritis of unspecified
cause; and (AGE4) gastroenteritis of unspecified type (e.g. ‘‘Diar-
rhoea and vomiting”; codelists available on request).
To accommodate multiple consultations for an ongoing illness,
AGE diagnostic codes recorded 628 days after a previous consulta-
tion were considered part of the same AGE episode. The first con-
sultation within the episode was the incident date of that episode.
Episodes of AGE first seen and diagnosed in hospital or in EDs
(identified from the consultation type in the CPRD data) were
excluded, to restrict analyses to AGE diagnosed in primary care.
We then excluded episodes unlikely to be rotavirus AGE, namely
episodes of non-infectious AGE of specified type (AGE2), and epi-
sodes of possible chronic diarrhoea, identified as AGE of unspeci-
fied type (AGE4) in individuals with pre-existing conditions that
cause chronic diarrhoea (large bowel cancer, inflammatory bowel
disease, irritable bowel syndrome, coeliac disease, cystic fibrosis,
chronic pancreatitis, post-gastrectomy syndromes, post-bariatric
surgery conditions or radiation colitis). In line with previous stud-
ies, non-infectious AGE of unspecified cause (AGE3) was retained
in the primary analysis because previous investigations indicate
that this is often a miscoding for infectious AGE [3,10].
Covariates of interest included age, subdivided into year of age
for the first 5 years, then 5–14, 15–44, 45–64 and 65+ years; rota-
virus epidemiological year (July-June); rotavirus season, classified
based on historical rotavirus laboratory reports into high
(February-April), medium (October-January, May) and low season
(July-September, June). In each rotavirus year, temperature and
rainfall were based on the median values of the daily mean central
England temperature and rainfall for the two winter months (Jan-
uary, February) that captured the weather in the period spanning
the start of rotavirus high season each year.
We performed age-stratified time series analyses of monthly
counts of incident AGE cases, using negative binomial regression
with an offset for the denominator (age-specific person-time). We
included a variable in the model for the post-vaccination period to
obtain adjusted incidence rate ratios (IRRa) compared with the
pre-vaccinationperiod. Yearwas added to themodel as a linear term
to account for underlying secular trends. We initially considered
using a longer pre-vaccination period (starting July 2003), but AGE
counts in the earliest years were unusually low, which resulted inK primary care (per 100,000 person years), July 2008-April 2015.
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lating beyond the pre-vaccination era. We therefore modelled the
data in the five years before vaccine introduction, duringwhich time
AGE incidencedecreased linearly.Wealso tested the addition of var-
ious combinations of the two weather variables to our model,
including temperature and rainfall added separately, or added
together with and without interaction terms (including interactionFig. 2. Comparison of post-vaccination incidence of AGE seen in primary care (episodes p
2015.with each other and with rotavirus season). The association of each
combination of temperature/rainfall with AGE incidence was
assessed using likelihood ratio tests, and the effect on each IRRa of
adjusting for the weather variables was examined.
As in our previous hospitalisation analyses, we assessed auto-
correlation by examining the residuals from the models, but found
that the estimates and standard errors for the vaccine indicatorer 100,000 person years) in young children, stratified by year of age, July 2008-April
S.L. Thomas et al. / Vaccine 35 (2017) 680–686 683variable were very similar with and without lag terms and thus
these terms were not included in the final models [10].
In sensitivity analyses, we restricted the data to episodes of
infectious and unspecified AGE only (AGE1 and AGE4). We also
generated IRRa estimates for each post-vaccination year separately
(2013–14 and 2014–15).2.3. Cases and healthcare costs averted
We calculated the number of healthcare contacts for AGE that
were averted among children aged <5 years in the first year after
vaccine introduction, including general practice consultations, hos-
pital admissions and ED attendances.
For general practice, the number of incident AGE cases averted
in England were derived from the time-series models, using the
expected number of AGE episodes in 2013–14 predicted by the
model and the age-stratified IRR, and extrapolating the numbers
to the England child population. The total number of general prac-
tice consultations averted in each age group were then calculated
by multiplying the number of incident cases averted in that age
group by the average number of GP consultations per AGE episode.
The numbers of hospitalisations averted were derived similarly,
from our previous time series analyses of England-wide hospitali-
sation data (July 2007-June 2014) [10]. For AGE ED visits averted,
we used EDSSS data collected between July 2012 and June 2014;
each week, data were restricted to the EDs that reported fully for
every day of that week. As not all EDs were included weekly, we
estimated total AGE visits each week by calculating the proportion
of all ED visits each week that were AGE (from those that did
report), and multiplying this by the estimated average weekly
number of all ED visits in England during the study period. To esti-
mate this average wemultiplied the weekly average number of vis-
its per ED in those reporting in our study period by the number of
ED departments in England [18]. The number of AGE cases averted
in EDs was obtained by subtracting the calculated number of AGE
visits during the rotavirus season (weeks 5–17 inclusive) in
2013/14 from the numbers in the same period in 2012/13.
Costs were calculated using a number of data sources; details of
calculations are in Supplementary Appendix [19]. The healthcare
costs averted were calculated by multiplying the number of
healthcare visits averted by the cost of the visit for each age group,
then summed across the type of healthcare visit (hospital, GP orTable 1
Incident AGE episodes seen in general practice before and after rotavirus vaccine introduc
Number of incident AGE episodes
Age (years) Pre-introduction Mean
(minimum)
2013–14
Observed
2014–15
Observed
<1 13,029 (12,337) 8709 6068
1 10,096 (9367) 6090 4101
2 4808 (4347) 3223 2340
3 2952 (2705) 2068 1457
4 2145 (2017) 1597 1118
5–14 9573 (9023) 7399 5103
15–44 33,736 (30,880) 26,044 17,473
45–64 23,064 (21,707) 18,144 12,130
65+ 28,664 (27,600) 23,917 16,822
a Incidence rate ratio (compared to the pre-introduction period), adjusted for monthED). To generate a distribution of annual costs averted, we sampled
100,000 times from each of the listed distributions (for costs), from
the respective lognormal distributions (for predicted number of GP
visits and hospital visits), and from the normal distribution (for
predicted number of ED visits). We report the mean costs averted
with their 95% prediction intervals, overall and stratified by health-
care setting and age.
We analysed data using STATA MP v.13.1 (StatCorp, College Sta-
tion, TX) and MATLAB R2014b version 8.4.0 (Natick, Mas-
sachusetts:The MathWorks Inc., 2014)
3. Ethics approval
Approval was received from the Independent Scientific Advi-
sory Committee of the Medicines and Healthcare Products Regula-
tory Agency (ISAC number: 15_066R) and the Ethics Committee of
the London School of Hygiene & Tropical Medicine (Reference
number: 11843).
4. Results
Between 1st July 2008 and 30th April 2015, after excluding 845
episodes of non-infectious AGE of specified type and 160,550 epi-
sodes of chronic diarrhoea, there were 804,141 incident episodes
of AGE seen in general practice during 29,228,316 person-years
of follow-up. In children aged <5 years, most (81.6%) of the
201,921 AGE episodes were categorised as non-specific gastroen-
teritis, with 18.3% categorised as infectious and 0.1% as non-
infectious of unspecified cause. For older children/adults, the rela-
tive percentages were 76.8%, 23% and 0.2% respectively. Only 0.2%
of episodes (1634 episodes in children <5 yrs, 453 episodes in older
children/adults) were labelled specifically as rotavirus AGE.
Before vaccine introduction, incident AGE consultations fol-
lowed the expected seasonal pattern with annual peaks in
February-March. Incidence decreased markedly after vaccine
introduction, with a complete loss of the seasonal peak for both
2013–14 and 2014–15 (Fig. 1). The decrease was most marked in
young children targeted for vaccination (aged <2 years between
July 2013 and April 2015, Fig. 2), but was also seen to a lesser
extent in older children and in adults (Supplementary Figure),
suggesting herd immunity. For younger children, the monthly
AGE rates in rotavirus season (February-April) remained lower intion in England.
2013–14 IRRa
(95% CI)
p value 2014–15 IRRa
(95% CI)
p value Overall IRRa
(95% CI)
0.85
(0.76,0.95)
0.0050 0.85
(0.74,0.97)
0.0145 0.85
(0.76,0.95)
0.79
(0.69,0.90)
0.0005 0.79
(0.67,0.93)
0.0051 0.79
(0.69,0.90)
0.87
(0.79,0.96)
0.0062 0.93
(0.83,1.05)
0.2411 0.89
(0.81,0.98)
0.88
(0.79,0.98)
0.0192 0.92
(0.81,1.05)
0.2008 0.89
(0.81,0.99)
0.86
(0.78,0.96)
0.0061 0.87
(0.77,0.99)
0.0378 0.87
(0.79,0.96)
0.92
(0.86,0.99)
0.0284 0.92
(0.84,1.00)
0.0484 0.92
(0.86,0.99)
0.95
(0.90,1.00)
0.0592 0.94
(0.88,1.00)
0.0658 0.95
(0.90,1.00)
0.92
(0.87,0.97)
0.0042 0.89
(0.83,0.95)
0.0006 0.91
(0.86,0.96)
0.94
(0.89,1.00)
0.0403 0.95
(0.89,1.01)
0.1128 0.94
(0.90,1.00)
and rotavirus epidemiological year.
Fig. 3. Adjusted incidence rate ratios (IRR) for the incidence of AGE in the post-vaccination period (July 2013-April 2015) compared with the pre-vaccination period, stratified
by age and rotavirus season.
Table 2
Estimated AGE cases and costs averted in general practice, hospital and Emergency Departments in 2013/14 among children aged <5 years in England.
Age (years) Annual visits averted 2013/14 (95% prediction interval) Annual costs averted (2014 £million)
(95% prediction interval)
GP Hospital EDs GP Hospital EDs
<1 22,977 (6466,40,892) 5300 (2807,8043) 4579 (3284,5873) 1.001 (0.266,1.935) 3.556 (1.841,5.532) 0.557 (0.377,0.760)
1 26,147 (10,458,43,499) 4731 (1872,8068) 5658a (2917,8399) 1.112 (0.412,2.023) 3.175 (1.237,5.521) 0.688a (0.344,1.069)
2 7336 (1964,13,118) 1591 (545,2788) 0.304 (0.077,0.591) 1.068 (0.361,1.907)
3 4243 (650,8131) 722 (181,1329) 0.176 (0.026,0.364) 0.484 (0.120,0.908)
4 3755 (1010,6725) 339 (-2, 715) 0.156 (0.040,0.303) 0.228 (-0.1,0.487)
All ages 64,457 (40,246,90,135) 12,683 (8600,17,123) 10,236 (7206,13,265) 2.749 (1.496,4.343) 8.511 (5.570,1.1873) 1.245 (0.830,1.715)
Total 87,376 (62,588,113,561) 12.505 (9.209,16.198)
a Ages 1–4 years combined.
684 S.L. Thomas et al. / Vaccine 35 (2017) 680–686the two years after vaccine introduction than the lowest monthly
rate for the same period pre-2013 (Fig. 2).
In multivariable analyses, general practice AGE rates in infants
dropped by 15% in the post-vaccination period overall (IRRa = 0.85;
95%CI = 0.76–0.95, Table 1). A graded decrease was seen across the
year, with a 41% reduction in high rotavirus season (IRRa = 0.59;
95%CI = 0.53–0.66) and a 19% reduction in the medium season,
but no evidence of a decrease in low season (Fig. 3). Similar
decreases were seen for children aged 1 year, with 2013–15 rates
dropping by 21% overall and by 50% in high season (Table 1,
Fig. 3). Decreases of 11–13% (25–28% in high season) were seen
in children aged 3–5 years. For older children and adults there
was less strong evidence of a decrease overall, but rates dropped
by 12–16% in high season. The reductions were similar in both
post-vaccination years (Table 1). Temperature and rainfall (added
to the models in any of the planned combinations) had a negligible
effect on the adjusted rate ratios (data not shown).
The estimated number of cases averted in young children seek-
ing healthcare services in England in 2013–14 are summarised in
Table 2. An estimated 64,457 AGE cases were averted in general
practice, 10,236 cases in EDs, and 12,683 in hospitalisations. This
translated into averted healthcare costs of £12.5 million (95% pre-
diction interval: 9.21–16.20; Table 2).
5. Discussion
Our analyses can be considered the equivalent of a vaccine
probe study, in that the reduction in the AGE burden seen after
rotavirus vaccine introduction can be attributed to prevention of
AGE cases caused by the vaccine-specific pathogen (rotavirus).
The vaccine had high uptake among infants (the target vaccinationgroup), and our analyses show marked decreases in incident AGE
episodes among children aged <2 years seen in general practice
in the two years after vaccine introduction. Notably, there was
complete loss of the seasonal peak in the months of historically
high rotavirus circulation. Similar reductions in AGE were also seen
in other young children who were ineligible for rotavirus vaccina-
tion, and to a certain extent in older individuals, suggesting herd
immunity. Across healthcare settings in England, we estimated a
large number of AGE cases averted among children aged <5 years
in the first year of vaccine introduction, with appreciable health
care costs averted.
The marked reductions in AGE cases in general practice echo
earlier findings of decreased numbers of laboratory-confirmed
rotavirus infections and AGE hospitalisations in England following
implementation of rotavirus vaccination [10]. Assessment of the
impact of rotavirus vaccination has focused in most countries on
reductions in rotavirus- or all-cause AGE hospitalisations, but the
impact on primary care has been less studied. Initial analyses of
UK general practice data in the first post-vaccination year using
rapid syndromic surveillance methods showed reductions of 26–
30% in gastroenteritis consultations (GP in-hours and out-of-
hours respectively) among infants during high rotavirus season
[11]. A later window for rotavirus activity was used (weeks
14–22 for GP in-hours), which may explain the slightly lower
reductions compared to our study. Also, the pre-vaccination era
data used were restricted to the year before vaccine introduction.
Our study combined different modes of AGE (incorporating diar-
rhoea and vomiting consultations) to provide a composite estimate
of incidence. We also modelled pre-vaccination incidence over a
longer period and extended analyses to the second year after
vaccine introduction (to the end of high rotavirus season) to show
S.L. Thomas et al. / Vaccine 35 (2017) 680–686 685continued reduction. Our estimate of an overall 15% reduction in
general practice AGE burden in infants is similar to that in Finland
for infant outpatient AGE visits after vaccine introduction [20]. Our
estimated 41% reduction in peak season is also broadly consistent
with findings from 33 ambulatory paediatric practices in the USA,
which reported a 33% reduction in peak AGE rates in children aged
62 years by the end of the second year of vaccine introduction, in a
population with lower vaccine coverage than in the UK [6].
Our estimates of the number of AGE cases averted among young
children and their associated healthcare costs update earlier esti-
mates from the pre-vaccination era (1995–2003) [3]. The earlier
study estimated the AGE healthcare burden attributable to rota-
virus infection in children aged <5 years in England and Wales
(using regression modelling of seasonal laboratory data against
AGE cases), with estimated healthcare costs of £14.2 million. There
are several likely explanations for our somewhat lower estimate.
Our analyses were for England only, and vaccine effectiveness
and vaccine coverage are not 100%; thus not all rotavirus AGE cases
will have been averted. Consultations for AGE in general practice
have been falling over time; our estimates from a later era reflect
this declining AGE burden, accentuated by our removal of AGE
cases diagnosed in EDs or in hospital to avoid double-counting of
AGE events [3]. The estimated proportions of AGE cases attributa-
ble to rotavirus in seasonal regression modelling depend on the
incidence of other causes of AGE in young children, and these
may have changed over time. The earlier estimate of AGE burden
in EDs was based on only five hospitals in the Greater London area,
which may have been less generalisable than our ED sample [3].
Finally, the earlier investigation included an estimated £0.56 mil-
lion due to NHS Direct calls; we did not have updated data to
add these costs to our analyses.
We deliberately restricted estimates of healthcare costs averted
to young children, to compare with previous analyses and to focus
on the age group in which rotavirus is the commonest cause of
AGE. Our estimates are thus conservative, as they exclude probable
AGE cases averted in older children and adults due to herd immu-
nity and cases averted in additional healthcare settings (such as
NHS Direct and NHS 111), and made conservative estimates of
other healthcare costs.
Our study has many strengths. Our use of a large general
practice data source, an episode structure for AGE and a wide range
of AGE diagnostic codes allowed us to capture episodes recorded
using symptom codes, and identify AGE subgroups. The choice of
AGE as an outcome rather than laboratory-confirmed cases
avoided major underestimation of the impact of vaccine introduc-
tion due to the rarity of microbiological testing of AGE specimens,
especially in general practice. Multivariable analyses using pre-
vaccination data over several years allowed adjustment for under-
lying trends in AGE incidence and health-seeking behaviour, and
the potential effects of weather. CPRD patients have been shown
repeatedly to be representative of those in the United Kingdom
as a whole, and thus our results should be generalizable to the
UK population [12].
Some limitations need consideration. These are ecological anal-
yses, and the decrease in AGE we found in the post-vaccination era
could be due to factors other than introduction of vaccination. The
UK experienced an exceptionally mild and wet winter in 2013/14,
which may have decreased rotavirus activity. Low AGE incidence
was also seen in 2013/14 in the Netherlands, a country that has
not introduced rotavirus vaccination; suggested reasons for this
lower incidence included the mild winter, high rotavirus incidence
the previous year, and rotavirus vaccination in neighbouring coun-
tries [21]. Our detailed investigation of the effects of temperature
and rainfall on AGE trends indicated that these were not major
contributors. We also found very similar reductions in AGE in the
second post-vaccination year, whereas in the Netherlands AGEincidence returned to previous levels (Susan Hahne, personal
communication). Thus it is likely that the reduction in AGE we
found is mainly due to the rotavirus vaccination programme.
Another possible limitation relates to the relatively small number
of available ED units, with only a single pre-vaccination year for
comparison as the EDSSS was set up to provide enhanced surveil-
lance for the London 2012 Olympic and Paralympic Games. Thus,
the ED estimates may be less robust than those obtained for gen-
eral practice and hospitalisations.
In conclusion, we have demonstrated substantial decreases in
AGE in general practice in the first two years of the vaccination
programme, with new estimates showing appreciable healthcare
costs averted. Continued monitoring of AGE incidence in all health-
care settings in England is important. Analyses of individual-level
data are now underway to estimate vaccine effectiveness in differ-
ent settings.
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